Add BrightSurf on Google Email

Major uncertainties remain about impact of treatment for gender related distress

Two pooled data analyses suggest that puberty blockers and gender-affirming hormone therapy have no conclusive evidence on their effectiveness or impact on mental and physical health. The findings echo the Hilary Cass review, concluding that the evidence is wholly inadequate to gauge the effectiveness of these treatments.

SourceBMJ Group·JournalArchives of Disease in Childhood·TypeSystematic review·DateJan 23, 2025

Study identifies mechanism underlying increased osteoarthritis risk in postmenopausal females

A new study identifies the molecular mechanisms underlying increased osteoarthritis risk in postmenopausal females, revealing that menopause-induced changes in sex hormone levels contribute to joint degeneration. Restoring these hormones may protect against cartilage degeneration, paving the way for novel treatments.

SourceMass General Brigham·JournalNature Aging·TypeExperimental study·DateJan 16, 2025

Trastuzumab emtansine improves long-term survival in HER2 breast cancer

The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.

SourceUniversity of Pittsburgh·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJan 15, 2025

Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases

A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...

Selenium nanoparticles: A new frontier in immunotherapy and disease treatment

Researchers are discovering selenium nanoparticles' potential in cancer prevention, inflammation reduction, and tumor treatment through their ability to activate the immune system and reduce inflammation. SeNPs are also being explored as vaccine adjuvants to improve immune cell activation and boost cancer vaccine efficacy.

SourceShanghai Jiao Tong University Journal Center·JournalNano Biomedicine and Engineering·DateDec 25, 2024

Pyrotinib and fulvestrant combination shows promising efficacy for HR+/HER2+ metastatic breast cancer patients

The study demonstrated a median progression-free survival of 18.2 months and a disease control rate of 97.5% among participants with hormone receptor-positive and HER2-positive metastatic breast cancer. The combination treatment was well-tolerated, with no grade 4 adverse events reported.

Brain inflammation alters behaviour according to sex

Researchers found that neuroinflammation in the hippocampus significantly alters motivation and behaviour in mice, particularly in females. This study suggests that treatments targeting hippocampal neuroinflammation could help reduce cognitive and behavioural symptoms in diseases such as Alzheimer's and Depression.

SourceUniversity of Technology Sydney·JournalBrain Behavior and Immunity·TypeExperimental study·DateDec 18, 2024

Flavonoids in polyphenols: Activating gut hormones to improve health

Researchers found that flavonoids in everyday foods like green tea and dark chocolate regulate glucose levels through gut receptors, paving the way for better health management. The study highlights the potential of polyphenol-rich diets to improve public health and offers a foundation for developing new therapies.

SourceShibaura Institute of Technology·JournalCurrent Research in Food Science·TypeComputational simulation/modeling·DateDec 17, 2024

Next-generation SERD protects against progression in some patients with advanced breast cancer resistant to standard hormone therapy

The EMBER-3 clinical trial showed that imlunestrant improved progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer, particularly those with ESR1 mutations. The combination of imlunestrant and abemaciclib also demonstrated a significant reduction in risk of progression or death.

SourceAmerican Association for Cancer Research·JournalNew England Journal of Medicine·DateDec 11, 2024

SABCS: Improved survival for advanced breast cancer, using genomics to identify patients with high risk of recurrence, how race/ethnicity influence the risk of heart failure in early-stage breast cancer and more

Researchers at UCLA Health presented several breakthroughs at the San Antonio Breast Cancer Symposium, including improved survival rates for advanced breast cancer patients who receive trastuzumab deruxtecan (T-DXd), a novel ADC. Additionally, new genomic testing and circulating tumor DNA analysis may help identify high-risk patients a...

New study finds neurobiological evidence of peripartum depression in women, distinguishing it from major depressive disorder

Researchers have identified structural grey matter differences in the brains of women with a history of peripartum depression compared to those without. The study found that hormone fluctuations during pregnancy and childbirth may be key to understanding this condition.

SourceElsevier·JournalBiological Psychiatry Cognitive Neuroscience and Neuroimaging·TypeImaging analysis·DateDec 5, 2024

Pioneering neuroendocrinologist shapes brain research at 100 while still making discoveries

Dr. Seymour Reichlin's centennial celebration highlights his ongoing scientific impact, with recent collaborations yielding new insights into hormone therapies for cognitive enhancement and emotional homeostasis. His work has established neuroendocrinology as a distinct field, bridging neuroscience, endocrinology, and clinical medicine.

SourceGenomic Press·JournalBrain Medicine·TypeNews article·DateDec 3, 2024

Boston Medical Center and Boston University researchers one step closer to developing cell-based therapy for hypothyroidism

Boston Medical Center and Boston University researchers have made a breakthrough in developing cell-based therapy for hypothyroidism. They derived transplantable thyroid follicular epithelial cells from human induced pluripotent stem cells, which can be transplanted into thyroid-deficient animal models.

SourceBoston Medical Center·JournalStem Cell Reports·DateNov 7, 2024

Menopausal hormone therapy use among postmenopausal women

A cross-sectional study found that menopausal hormone therapy use has decreased significantly over the past two decades among US postmenopausal women. Notably, women from racial and ethnic minority groups had lower rates of menopausal hormone therapy use compared to non-Hispanic white women.

SourceJAMA Network·JournalJAMA Health Forum·DateSep 27, 2024

Chinese Medical Journal investigates recent and future trends of lung cancer

According to the Global Cancer Observatory (GLOBOCAN), lung cancer is the most common type of cancer, with 2.2 million new cases and 1.8 million deaths worldwide in 2020. China had the highest number of new cases, and incidence and mortality rates have been steadily rising from 1990 to 2019.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeData/statistical analysis·DateSep 26, 2024

Study helps predict how long it will take for testosterone to return to normal after prostate cancer treatment

A new study has found that baseline testosterone, age, and duration of ADT are key predictors of testosterone recovery. The researchers developed a nomogram to estimate recovery times based on patient-specific characteristics, providing valuable insights for improving patient outcomes.

Women with premature ovarian insufficiency are at greater risk of severe autoimmune diseases

A large study found that women with premature ovarian insufficiency are 2.6 times more likely to have an autoimmune disorder, with some conditions increasing the risk by 26 times. The study suggests a strong link between POI and severe autoimmune diseases, highlighting the need for medical professionals to be aware of this increased risk.

SourceEuropean Society of Human Reproduction and Embryology·JournalHuman Reproduction·TypeObservational study·DateSep 25, 2024